Terms ending in 2036
Every in-force patent on Acceleron Pharma Inc.'s record whose computed term ends in 2036, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 9,975,934 | Follistatin-Related Fusion Proteins In force · High confidence | Acceleron Pharma Inc. | In force | High confidence | |
| US 11,001,614 | Method for Treating a Muscle-Related Disorder with Follistatin-Related Fusion Proteins In force · Medium confidence | Acceleron Pharma Inc. | In force | Medium confidence | |
| US 10,227,393 | Tgf-Beta Superfamily Type I and Type II Receptor Heteromultimers and Uses Thereof In force · High confidence | Acceleron Pharma Inc. | In force | High confidence | |
| US 10,738,098 | ALK4:ACTRIIB Heteromultimers and Uses Thereof In force · High confidence | Acceleron Pharma Inc. | In force | High confidence | |
| US 10,906,958 | Tgf-Beta Superfamily Type I and Type II Receptor Heteromultimers and Uses Thereof In force · High confidence | Acceleron Pharma Inc. | In force | High confidence | |
| US 11,028,145 | ALK7:ACTRIIB Heteromultimers and Uses Thereof In force · High confidence | Acceleron Pharma Inc. | In force | High confidence | |
| US 11,279,746 | ALK4:ACTRIIB Heteromultimers and Uses Thereof In force · High confidence | Acceleron Pharma Inc. | In force | High confidence | |
| US 11,857,599 | Compositions and Methods for Treating Spinal Muscular Atrophy In force · High confidence | Acceleron Pharma Inc. | In force | High confidence | |
| US 12,024,563 | ALK7 Antagonists and Uses Thereof In force · High confidence | Acceleron Pharma Inc., | In force | High confidence | |
| US 10,196,434 | ALK4:ACTRIIB Heteromultimers and Uses Thereof In force · High confidence | Acceleron Pharma Inc. | In force | High confidence | |
| 10 more term ends in 2036 · Pro | |||||
10 of 20 patents shown. Soonest term end first, then patent number.
Pro members see all 20.
17 of these are in force and held by Acceleron Pharma Inc..
Updated Nov 19, 2026 · includes USPTO assignment data published Nov 18, 2026, status data published Nov 19, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.